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Abstract 
Background: The Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed generic questionnaire that 
consists of 14 items assessing health status in people with musculoskeletal disorders. The objective was to translate 
and cross-culturally adapt the MSK-HQ into Norwegian and to examine its construct validity and reliability in people 
on sick leave with musculoskeletal disorders.
Methods: A prospective cohort study was carried out in Norway on people between 18 and 67 years of age and sick 
leave due to a musculoskeletal disorder. The participants were recruited through the Norwegian Labour and Welfare 
Administration during November 2018–January 2019 and responded to the MSK-HQ at inclusion and after four weeks. 
Internal consistency was assessed by Cronbach’s alpha, and structural validity with a factor analysis. Construct validity 
was assessed by eight “a priori” defined hypotheses regarding correlations between the MSK-HQ and other reference 
scales. Correlations were analyzed by Spearman’s- or Pearson’s correlation coefficient and interpreted as high with 
values ≥ 0.50, moderate between 0.30–0.49, and low < 0.29. Reliability was tested with test–retest, standard error of 
measurement (SEM) and smallest detectable change (SDC).
Results: A total of 549 patients, mean age (SD) 48.6 (10.7), 309 women (56.3%), were included. The mean (SD) 
MSK-HQ sum scores (min–max 3–56) were 27.7 (8.2). Internal consistency was 0.86 and a three-factor structure was 
determined by factor analysis. Construct validity was supported by the confirmation of all hypotheses; high correla-
tion with HRQOL, psychosocial risk profile, and self-perceived health; moderate correlation with physical activity, 
self-perceived work ability, and work presenteeism; and low correlation with the number of sick days. The test–retest 
reliability was good with an intraclass correlation coefficient of 0.83 (95% CI, 0.74–0.89), SEM was 2.3 and SDC 6.5.
Conclusions: The Norwegian version of the MSK-HQ demonstrated high internal consistency, a three-factor struc-
ture, good construct validity and good test–retest reliability when used among people on sick leave due to musculo-
skeletal disorders.
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Introduction
Musculoskeletal (MSK) disorders cause major health 
challenge and burden for individuals, health systems and 
social care worldwide [1, 2]. General MSK disorders such 
as osteoarthritis, inflammatory conditions, back, neck, 
shoulder and knee pain have been the single greatest 
cause of years lived with disability for many years [1].
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Patients with MSK pain in different body regions tend 
to share the same prognostic factors, supporting the use 
of generic patient-reported outcome measures (PROMs) 
[3, 4]. The lack of generic questionnaires for people with 
MSK disorders argues for development and validation of 
new tools for assessment of this wide group of disorders. 
Due to the similar characteristics and prognostic fac-
tors for MSK disorders one questionnaire might be suf-
ficient to assess necessary contents. The Musculoskeletal 
Health Questionnaire (MSK-HQ) is a recently developed 
PROM that assesses health status in people with MSK 
disorders [5]. The questionnaire is one of few tools made 
specifically for assessment of MSK disorders, and given 
its generic form, it is appropriate for assessing and com-
paring numerous MSK disorders [6]. MSK-HQ is avail-
able in English and besides the original study, two studies 
have performed validation of the English questionnaire 
[7, 8]. The development of the MSK-HQ included a scop-
ing exercise to identify domains important for MSK 
health and a qualitative evaluation of face and content 
validity [5]. Further on, assessment of construct valid-
ity, test–retest reliability and data quality have been con-
ducted with acceptable results [5, 7, 9]. To expand the 
use of MSK-HQ to Norway, a translation process and 
assessment of its psychometric properties are essential. 
Therefore, the aim of this study is to translate and cross-
culturally adapt the MSK-HQ into Norwegian and to 
examine its validity and reliability in people on sick leave 
due to musculoskeletal disorders.
Methods
Translation and cross‑cultural adaption
The MSK-HQ is a generic questionnaire that consists of 
14 questions concerning MSK health during the last two 
weeks, including domains as pain, fatigue, physical func-
tion, sleep, self-efficacy, and psychological well-being [5]. 
The questions are answered using a 5-point ordinal scale, 
from “not at all” (4) to “extremely” (0). Questions 12 and 
13, concerning self-efficacy and health literacy, have their 
response in reversed order were “not at all” is scored 
zero. A 15th question, which is not part of the MSK-HQ 
total score, captures physical activity levels and is scored 
from 0 to 7. A sum of the first fourteen questions is used 
to calculate the MSK-HQ total score, and gives a result 
between 0 and 56, with higher scores reflecting better 
MSK health status.
The original English version of the MSK-HQ was 
translated into Norwegian after gaining approval from 
the original authors of the MSK-HQ [5]. The transla-
tion and cross-cultural adaption followed the guidelines 
proposed by Beaton et al., consisting of 6 stages [10]. In 
the first stage, two Norwegian translators fluent in Eng-
lish translated the items into Norwegian independently. 
The second stage consisted of a synthesis of the two 
translations. In the third stage, a back-translation was 
performed individually by two native English bilingual 
speakers. At the fourth stage, an expert committee con-
sisting of four translators, four of the authors of this arti-
cle and an additional two researchers from our research 
project reviewed the previous translations and reached 
a consensus on discrepancies before a prefinal version 
was produced. In the fifth stage, the prefinal version was 
completed by 25 people with MSK disorders who com-
mented on all aspects of the questionnaire. On the sixth 
and last step, the final version of the questionnaire was 
completed and submitted to the developers of the origi-
nal questionnaire.
Design and study population
The study was a prospective cohort study of people on 
sick leave due to MSK disorders [11]. The participants 
were recruited through the Norwegian Labour and Wel-
fare Administrations (NAV) webpages during November 
2018–January 2019. Eligible participants were invited to 
read project information and to consent electronically to 
participate. There were not any registration of the num-
ber of people that rejected the opportunity to participate. 
Eligible participants were people between 18 and 67 years 
of age and on sick leave for at least four weeks due to an 
MSK disorder. People on sick leave for other disorders or 
diseases or people not able to understand and write Nor-
wegian or English were excluded. All participants agreed 
to consent before being admitted to the study. The par-
ticipants answered the questionnaire electronically at 
baseline, and were asked to respond a second time after 
four weeks. The MSK-HQ was part of a comprehensive 
questionnaire used in the study. This study was carried 
out in two phases. First a translation and cross-cultural 
adaption of the original MSK-HQ into Norwegian. Sec-
ond, the Norwegian version of the MSK-HQ was tested 
for its psychometric properties.
Measurements
In addition to the Norwegian version of the MSK-HQ 
(including item 15 on physical activity), the baseline 
questionnaire consisted of sociodemographic data, 
medical history, MSK diagnosis (ICPC-2), and differ-
ent PROMs, and is presented in the published proto-
col [11]. Several reference scales and single items were 
used to evaluate construct validity: first, the EuroQol 5 
Dimensions (EQ-5D-5L), which covers five dimensions 
within health-related quality of life (HRQOL): mobility, 
self-care, daily activities, pain/discomfort and anxiety/
depression [12]. Second, the Örebro Musculoskeletal 
Pain Screening Questionnaire short form (ÖMPSQ-SF), 
which is a widely used screening questionnaire used for 
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early identification of yellow flags and patients at risk 
of developing work disability due to pain [13]. Third, 
the Keele Subgroups for Targeted Treatment (the Keele 
STarT MSK) tool, which is a questionnaire developed 
to assess risk of poor outcome and enable risk stratifica-
tion for people with MSK disorders [14, 15]. The single 
items are the EQ-5D Visual Analogue Scale (0–100 VAS), 
from the EQ-5D-5L assessing self-perceived health [12], 
presenteeism assessed with item 9 from the Institute 
for Medical Technology Assessment Productivity Cost 
Questionnaire (iPCQ) [16], and a self-perceived work 
ability question ranging from 0–10 [17]. Additionally, the 
participants’ number of sick days for the last 12 months 
were summarized using registry data from the NAV. The 
number of sick days was measured as calendar days and 
adjusted for percentage of sick leave.
For test–retest purposes, a follow-up questionnaire was 
collected four weeks after baseline that contained the 
same questions as in the baseline questionnaire. In addi-
tion, it included a seven-point global rating of change 
scale, ranging symptoms from “very much worse” to 
“much better”. To ensure that change in symptoms would 
not influence the results, only participants rating “no 
change” in symptoms were included in the test–retest 
subgroup and the assessment of test–retest reliability.
Statistical analysis
IBM SPSS Statistics for Windows, version 26.0 (IBM 
Corp, Armonk, NY) was used for all data analyses. 
Descriptive analyses included means (SD) and frequen-
cies (%). The sample size was based on the quality criteria 
suggested by Terwee et  al., with at least 50 participants 
needed for assessing interpretability with floor or ceil-
ing effects, and minimum 100 people for assessing inter-
nal consistency and construct validity, and conducting 
factor analysis [18]. The distribution of normality was 
assessed with the Kolmogorov–Smirnov test and by vis-
ual inspection of the distribution plot. Construct validity 
was assessed by formulating and testing of eight “a priori” 
defined hypotheses regarding the correlation between 
MSK-HQ and other constructs [19]. Test–retest reliabil-
ity was determined by calculating the single measures 
intraclass correlation coefficient (ICC) with a two-way 
random effects model, absolute agreement (2,1). An ICC 
value above 0.7 was considered acceptable [18].
Factor analysis by a principal component analysis was 
performed on the results to determine structural valid-
ity. Retained factors had an eigenvalue > 1, and independ-
ent factors were obtained by the use of oblique rotation, 
direct oblimin.
The internal consistency reflects the interrelatedness 
among the items of the questionnaire, and the interrelat-
edness in the MSK-HQ was assessed with inspection of 
inter-item correlations and with Cronbach’s Alpha [19]. 
The value of Cronbach’s Alpha ranges from 0 to 1 and is 
considered acceptable when between 0.7 and 0.95 [18]. 
High values > 0.95 reflects high correlations between the 
items in the questionnaire and may indicate redundancy 
of one or more items [18].
The distribution of normality determined if paramet-
ric (Pearson’s correlation coefficient) or nonparamet-
ric (Spearman’s rank correlation coefficients) were used 
to assess the correlation between the constructs. The 
correlation coefficients were interpreted as being high 
when > 0.5, moderate when between 0.30–0.49, and low 
when < 0.29 [20]. The hypotheses used to assess construct 
validity were established based on the construct of the 
measures and former correlations of similar constructs. 
The MSK-HQ was hypothesized to have high correla-
tion with the EQ-5D-5L, the ÖMPSQ-SF and self-rated 
health. A moderate to high correlation was expected with 
the Keele STarT MSK, productivity loss, self-perceived 
work ability, and physical activity. A moderate to low 
correlation was hypothesized with sick leave 12 months 
before baseline. Construct validity was considered 
acceptable if 75% of the “a priori” hypotheses were con-
firmed [18].
Measurement error was assessed with stand-
ard error of measurement (SEM) and small-
est detectable change (SDC). The formula used for 
SEM was SEM =  SDdifference ÷ √2 and for SDC was 
SDC = SEM × 1.96 × √2 [21]. The agreement between 
the test and retest scores was assessed with a Bland–Alt-
man plot and the limits of agreement (95%) were calcu-
lated by the formula [mean difference ± 1.96 ×  SDdifference] 
[22].
To determine interpretability, floor and ceiling effects 
were analysed, and considered present if more than 15% 
of the participants scored the lowest or highest score, 
respectively [18, 23]. The number of participants with the 




During the forward and backward translations of the 
MSK-HQ, the expert committee found that the Norwe-
gian MSK-HQ was generally clear and understandable 
except for a few minor vocabulary adaptions to words 
and expressions in the items 1, 5, 6, 11 and 13. The pre-
liminary Norwegian translation of the words “severe”, 
“unable”, “interfered”, and “low in your mood” (item 1, 5, 
6, 11) were altered by the committee, as well as the head-
ing of item 13 (confidence in being able to manage your 
symptoms). The pilot testing on 25 people with MSK dis-
orders did not result in any changes in the wordings in 
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the MSK-HQ. The Norwegian MSK-HQ is presented in 
Appendix 1.
Participants and data quality
A total of 549 people completed the questionnaires 
online. Table  1 presents sociodemographic data and 
clinical variables for the whole sample and the test–retest 
subgroup at baseline. The MSK-HQ items were all man-
datory and participants were unable to go on without 
complete answers. Hence, there were no missing values 
in the questionnaire. The mean score of the MSK-HQ 
was 27.7 (8.2). The lowest score obtained was 3 points, 
while one person reached the highest score possible (56), 
indicating no floor or ceiling effects of the full question-
naire, presented in Table 2. There were three single items 
(3, 4 and 9) were > 15% of the participants answered the 
lowest or highest possible value (Table 2).
Structural validity
Before the factor analysis was performed, the suitabil-
ity of data was assessed. The correlation matrix showed 
presence of many coefficients above 0.3. The Kaiser–
Meyer–Olkin value was above the recommended value 
of 0.6 (0.83) and the Bartlett’s test of sphericity dem-
onstrated a significant value. The principal component 
Table 1 Baseline characteristics of the participants
ICPC-2 = International Classification of Primary Care,  2nd edition; MSK-HQ = Musculoskeletal Health Questionnaire; ÖMPSQ-SF = Ôrebro Musculoskeletal Pain 
Screening Questionnaire short form; iPCQ = iMTA Productivity Cost Questionnaire
Mean (SD) or N (%) Whole sample (n = 549) Test–retest 
subgroup 
(n = 101)
Age (yrs.) 48.6 (10.7) 48.8 (10.4)
Gender (% Women) 309 (56.3) 57 (56.4)
Civil status (%)
 Married/cohabiting 426 (77.6) 76 (75.2)
 Single/divorced 75 (13.7) 25 (24.8)
Education (> 12 years) (%) 220 (40.1) 39 (38.6)
L-diagnosis (ICPC-2) (%)
 Lower limb (L13-17) 47 (8.6) 10 (10.0)
 Upper limb (L08-12, L92-93) 121 (22.0) 16 (16.0)
 Neck (L01, L83) 36 (6.7) 3 (3.0)
 Low back (L02-03, L70, L84-86) 107 (19.5) 21 (20.9)
 Joint disorders (L88-91) 54 (9.8) 14 (13.9)
 Injuries and trauma (L72-81, L96) 51 (9.3) 7 (7.0)
 Other MSK diagnoses (L05, L07, L18-20, L26-29, L71, L82, L87, L94-95, L97-99) 133 (24.2) 30 (29.7)
Self-perceived work ability (0–10), median (range) 3 (0–10) 3 (0–9)
Self-rated health status/ EQ-VAS (0–100), mean (SD) 52.0 (21.1) 45.8 (21.0)
Physical activity (MSK-HQ q15), median (range) 2 (0–7) 1 (0–7)
Sick days the last year, median (range) 37.8 (2.3–239.2) 59.6 (13.1–237.1)
MSK-HQ (0–56), mean (SD) 27.7 (8.2) 24.9 (8.3)
Keele STarT MSK (0–12), mean (SD) 7.0 (2.4) 7.9 (2.0)
ÖMPSQ-SF (0–100), mean (SD) 55.4 (15.6) 61.8 (15.1)
iPCQ Q9 presenteeism (0–10), median (range) 5 (0–10) 5 (2–10)
EQ-5D-5L (− 0.59–1), median (range) 0.56 (− .35–1) 0.42 (− .35–.80)
Table 2 Descriptive statistics, floor and ceiling effects of the 
MSK-HQ items
MSK-HQ = Musculoskeletal Health Questionnaire






1 1.39 (0.7) .59 8.2 0.5
2 1.83 (1.0) .57 7.3 4.6
3 2.44 (1.2) .46 1.6 26.6
4 2.84 (1.0) .48 0.2 32.2
5 1.87 (1.2) .53 10.4 10.9
6 1.40 (0.8) .57 9.8 0.7
7 1.77 (1.0) .64 8.6 5.1
8 2.26 (1.0) .53 1.6 14.2
9 1.57 (1.2) .54 22.4 6.7
10 1.82 (1.1) .57 8.4 8.0
11 2.32 (1.1) .52 3.4 14.2
12 2.60 (1.0) .20 3.1 13.7
13 2.21 (0.9) .36 4.2 3.5
14 1.39 (0.7) .68 7.1 0.2
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analysis revealed that 3 factors exceeded eigenvalues of 
1 (5.3, 1.6 and 1.3) explaining a total of 60% (38%, 12% 
and 10%) of the variance (Table  3). Inspection of the 
scree plot showed a clear break after the third factor. 
Item 1, 2, 3, 5–8 and 14 loaded most strongly on factor 
1, item 11–13 loaded on factor 2, and item 2, 4, 9 and 10 
loaded factor 3. The inter-total correlation of the MSK-
HQ revealed that items 12 and 13 were less related to the 
other items, reflecting a different construct.
Internal consistency
The internal consistency was considered good after 
inspection of inter-item correlations and a Cronbach’s 
alpha value of 0.86.
Construct validity
Construct validity was assessed by testing eight “a pri-
ori” formulated hypotheses as presented in the left col-
umn of Table  4. Visual inspection of distribution plots 
and assessing Kolmogorov–Smirnov tests determined 
the normality distribution of the variables. The MSK-
HQ, ÖMPSQ-SF, Keele STarT MSK, and self-perceived 
health were normally distributed, while physical activ-
ity and number of sick days were left skewed, EQ-5D-5L 
and self-perceived work ability were skewed right, and 
presenteeism was uniformly distributed. The correla-
tion analysis (Table  4) demonstrated a high correlation 
between the MSK-HQ and EQ-5D-5L, ÖMPSQ-SF, Keele 
STarT MSK and self-rated health, a moderate correlation 
with presenteeism, self-perceived work ability and physi-
cal activity, and a low correlation with the number of sick 
days.
Reliability
The mean (SD) time between test and retest was 31 (5.4) 
days, and the questionnaire was answered by 330 partici-
pants. There were 101 (31%) participants that scored “no 
change” in the muscle and joint symptoms for the last 
four weeks, while 47 (14%) participants reported worse 
symptoms and 182 (55%) participants reported improve-
ment of symptoms. The total score of the MSK-HQ for 
the test–retest subgroup (N = 101) was mean (SD) 24.9 
(8.3) at baseline and 26.5 (7.9) at retest. The  ICC2.1 (95% 
CI) between test and retest was 0.83 (0.74–0.89). The cal-
culation of measurement error resulted in an SEM of 2.33 
and an SDC at 6.46. The mean difference between the test 
Table 3 Results of the explanatory factor structure by principal 
component analysis with loadings (n = 549)
Extraction Method: principal component analysis; oblique rotation with Kaiser 
normalization. Values below 0.3 are suppressed. The model explained 60% of the 
total variance; factor 1 explained 38%, factor 2 = 12% and factor 3 = 10%
Item Factor 1 Factor 2 Factor 3
1 Pain/stiffness during the day 0.45
2 Pain/stiffness during the night − 0.86
3 Walking 0.85
4 Washing/dressing − 0.39
5 Physical activity levels 0.84
6 Work/daily routine 0.65
7 Social activities and hobbies 0.59
8 Needing help 0.41
9 Sleep − 0.89
10 Fatigue or low energy − 0.58
11 Emotional well-being 0.42
12 Understanding of your 
condition and any current 
treatment
0.88
13 Confidence in being able to 
manage symptoms
0.84
14 Overall impact 0.48
Table 4 Construct validity: “a priori” formulated hypothesis
MSK-HQ = Musculoskeletal Health Questionnaire; MSK = Musculoskeletal.
Hypothesis Correlation value N Hypothesis 
confirmed?
A high score on the MSK-HQ (good MSK health) is expected to have high correlation with high health-related 
quality-of-life assessed by EQ-5D-5L
.764 541 Yes
A low score on the MSK-HQ (poor MSK health) is expected to have high/moderate negative correlation with a 
high score on the Örebro Musculoskeletal Pain Questionnaire short form.
− .659 549 Yes 
A low score on the MSK-HQ (poor MSK health) is high/moderate negative associated with high score on the 
Keele STarT MSK
− .689 549 Yes
A low score on the MSK-HQ (poor MSK health) is high/moderate associated with higher productivity losses. .336 237 Yes 
A low score on the MSK-HQ (poor MSK health) is high/moderate associated with low self-perceived work abil-
ity.
.412 548 Yes
A low score on the MSK-HQ (poor MSK health) is high associated with low self-rated health (EQ-VAS) .592 542 Yes 
A low score on the MSK-HQ, indicating poor MSK health, is high/moderate associated with few days with 
physical activity.
.378 535 Yes
A low score on the MSK-HQ (poor MSK health) is low/moderate associated with longer sick leave. .001 549 Yes
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and retest was − 1.6 points, with limits of agreement of 
7.26 and − 10.54 points (Fig. 1).
Discussion
In this study, the Norwegian version of the MSK-HQ was 
translated and showed to be a valid and reliable instrument 
to measure MSK health in people on sick leave due to an 
MSK disorder. The translation and cross-cultural adaption 
were successfully accomplished according to international 
guidelines [10], and the psychometric properties in terms 
of structural and construct validity, internal consistency 
and reliability were found to be good. Our results indicate 
that the MSK-HQ can be used in both clinical settings and 
research with the purpose of assessing people with MSK 
disorders.
In this study, the total score showed no floor and ceiling 
effects, which is consistent with former studies assessing 
the MSK-HQ [5, 7, 9]. Although, when assessing floor and 
ceiling effects at single items in this population, item 3 (gait) 
and item 4 (washing/dressing) demonstrated floor effects 
and item 9 (sleep) showed a ceiling effect.
The total score of the MSK-HQ was quite similar between 
the Norwegian and the British study populations. The Nor-
wegian population with different MSK disorders achieved 
a mean total score of 27.7, while the British populations 
scored a mean total score of 28.6 [5] and 26.6 [7]. The Dan-
ish population with MSK disorders, similar to our study, 
reached a higher mean score in both MSK-HQ (32.3) and 
EQ-5D-5L (0.69) [9]. One difference that might explain 
some of the differences is that only 7% of the Danish 
population was on sick leave and were possibly less affected 
of their MSK disorders [9]. Even though there are some dif-
ferences, the scores are within the measurement error of the 
MSK-HQ.
The factor structure was investigated and revealed a clear 
three-factor structure explaining 60% of the total variance. 
The general items formed the first factor, health literacy, 
self-efficacy and emotional well-being composed the sec-
ond factor, while the third factor consisted of fatigue and 
problems during the night. The three factors determined 
in these results might reflect how the questionnaire divides 
within three main domains or three subscales. Although, 
our results differs from a principal component analysis per-
formed in a previous study, where a one factor structure 
explained 63% of the variance, and a latent minor variable 
explained 10% of the item variance [7]. The minor variable 
of 10% consisted of item 12 and 13 (health literacy and self-
efficacy), which reflects similarities with the second factor 
of our study. Item 12 and 13 also achieved the lowest inter-
total correlation value among the questionnaire, which is 
similar to previous research [7].
The Norwegian MSK-HQ demonstrated high internal 
consistency, although a somewhat lower value than previ-
ous studies [5, 7, 9]. The items of the scale seemed to have 
high interrelatedness despite the different domains.
Based on a priori hypotheses, the Norwegian MSK-HQ 
demonstrated good construct validity. Previous studies 
have investigated the correlation between the MSK-HQ and 
HRQOL, and similar to our study the analyses showed a 
high correlation with EQ-5D-5L ranging from 0.78 to 0.81 
Fig. 1 Bland–Altman plot of mean difference and the Limits of agreement. Enlarged circles represent two identical values
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[5, 7]. The high correlation might reflect that the two ques-
tionnaires overlap in what they measure, hence the ques-
tionnaires can be redundant if used at the same patient or 
population. While the EQ-5D-5L with its five items is rela-
tively fast to answer, the MSK-HQ contributes insight to 
many useful domains, especially for clinicians. The 15 items 
give clinicians the possibility to target the intervention or 
information towards certain domains within the MSK-HQ. 
The other correlation values presented in Table  4 are also 
somewhat as expected, considering the relatedness of the 
constructs. High and similar correlations with the screen-
ing questionnaires ÖMPSQ-SF and the Keele STarT MSK 
reflect that they are assessing many of the same aspects and 
items, such as self-perceived function, pain, and distress. 
The last hypothesis with a high correlation was self-rated 
health, which also has close relations to several of the items 
in the questionnaires. Also, the MSK-HQ showed moderate 
correlations to the different aspects of work, productivity 
and self-perceived work ability, whereas the lack of correla-
tion with the number of sick days the last year is noteworthy. 
The broad range of domains in the MSK-HQ seems to have 
some overlap with the assessed questionnaires, although 
not redundant if used in a clinical setting or research. Due 
to the low correlation with former sick leave the question-
naire should not be used for predicting absenteeism. Due to 
few studies conducted concerning correlations between the 
MSK-HQ and other constructs, the eight hypotheses were 
rather broad, which could have influenced our chances of 
successfully confirming them. As the construct of MSK-HQ 
is investigated, further research should have the ability to 
specify and narrow down their hypotheses when assessing 
construct validity.
Assessment of the reliability resulted in a good test–retest 
in line with other studies conducted, which also demon-
strated good test–retest reliability with ICC values of 0.73–
0.86 [5, 7, 9]. Even though the test–retest subgroup reported 
“no change” in symptoms the last four weeks, a few outliers 
with are seen in Fig. 1. Particularly, more outliers and varia-
tion is seen in the upper end of the score. The measurement 
error of the MSK-HQ achieved good results with a low SDC 
of 6.46 points of the full range of the scale from 0–56. The 
implication of a low measurement error is that the ques-
tionnaire may be an appropriate outcome measurement to 
evaluate change during treatment or in a clinical setting. 
Although, one should keep in mind the variation seen in 
Fig.  1, and that the MSK-HQ demonstrated a somewhat 
higher estimate of measurement error in other populations 
[5, 7, 9], and further assessments are necessary to determine 
accurate values.
Our study conducted in a population on sick leave due 
to MSK disorders provides a good addition to previous 
research, which has been conducted on inflammatory 
arthritis, osteoarthritis and MSK disorders in primary care 
[5, 7, 9]. The fact that the MSK-HQ is a questionnaire for all 
MSK disorders might imply both weaknesses and strengths. 
Having one tool is a strength, because it helps to compare 
scores across different subgroups of MSK disorders. The 
location of the symptomatic body region might be of impor-
tance when using the MSK-HQ since people with different 
pain sites have different scores on the MSK-HQ [5]. The 
British study cohort consisted of 570 patients, including 
150 hip patients, 150 knee patients, and 60 patients with 
shoulder problems. The mean total score of the MSK-HQ 
varied from 24.9 (hip), 27.5 (knee), to 33.5 (shoulder) [5]. 
Hence, it is important for clinicians to be aware of this vari-
ation among anatomical body regions when interpreting the 
MSK-HQ scores.
One potential weakness of our study is the choice of 
design with four weeks between our test and retest. A 
period of 1–2 weeks is suggested in the literature, unless a 
good reason for another time frame is presented [18]. One 
could argue that the mean (SD) of 31 (5.4) days between 
the tests was a too long period. Therefore, we included a 
global rating of change scale to determine a population for 
the retest that reported having “no change” in symptoms 
the last four weeks, which has shown acceptable in a previ-
ous study on the MSK-HQ [9]. Another potential limitation 
is that the participants volunteered to join the study which 
might influence the degree of generalisability to the whole 
population of people on sick leave. A strength of this study is 
the large sample which is substantially more than the lower 
limits of the recommendations for the different analyses 
[18].
Conclusions
The results of this study suggest that the psychometric prop-
erties of the Norwegian version of the MSK-HQ in people 
on sick leave due to MSK disorders are good. The question-
naire seems appropriate for measuring domains related to 
MSK health in both research and clinical practice. Further 
investigations on different diagnoses and pain regions could 
be useful to determine differences in the total score.
Appendix
SPØRRESKJEMA OM MUSKEL‑ OG SKJELETTHELSE 
(MSK‑HQ)
Dette spørreskjemaet handler om dine ledd‑, rygg‑, 
nakke‑, skjelett‑ og muskelsymptomer slik som verk-
ing, smerter og/eller stivhet. Fokuser på den/de bestemte 
helseplagen(e) som du har søkt om behandling for her.
For hvert spørsmål, kryss (✓) av én boks for å markere 
hvilket utsagn som
best beskriver din situasjon de siste to ukene. 
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1. Smerte/stivhet i løpet av dagen
(Pain/stiffness during the day)
Hvor intense har dine smerter og/eller stivhet i muskler/ledd vært på dagtid de siste to ukene?
(How severe was your usual joint or muscle pain and/or stifness overall during the day in the last 
2 weeks)


















2. Smerter/stivhet om natten
(Pain/stiffness during the night)
Hvor intense har dine smerter og/eller stivhet i muskler/ledd vært om natten de siste
 to ukene?
(How severe was your usual joint or muscle pain and/or stiffness overall during the night
 in the last 2 weeks?)




















Hvor mye har symptomene hindret deg i å gå i løpet av de siste to ukene?
(How much have your symptoms interfered with your ability to walk in the last 2 weeks?)














Har ikke kunnet gå 
(Unable to walk)
 □ 0
4. Vaske seg/påkledning (Washing/Dressing)
Hvor mye har symptomene hindret deg i å vaske eller kle på deg de siste to ukene?
(How much have your symptoms
interfered with your ability to wash or dress yourself in the last 2 weeks?)
Ikke i det hele 












Klarer ikke å vaske eller 
kle på meg (Unable 
to dress myself )
 □ 0
5. Fysisk aktivitetsnivå (Physical activity levels)
Hvor vanskelig har det vært for deg å være så fysisk aktiv som du ønsker (f.eks. å gå en tur eller 
jogge) pga. ledd/muskel-symptomene de siste to ukene?
(How much has it been a problem for you to do physical activities (e.g. going for a walk or jogging)
 to the level you want because of your joint or muscle symptoms in the last 2 weeks?)
Ikke i det hele 












Ikke vært i stand til 
å være fysisk aktiv 
(Unable




Hvor mye har dine ledd-/muskelsymptomer begrenset deg i ditt arbeid eller daglige
 aktiviteter de siste to ukene (inkludert jobb og husarbeid)?
(How much have your joint or muscle symptoms interfered with your work or daily routine
 in the last 2 weeks (including work & jobs around the house)?)
Ikke i det hele 















7. Sosiale aktiviteter og hobbyer
(Social activities and hobbies)
Hvor mye har dine ledd-/muskelsymptomer hindret deg i å være sosialt aktiv og å holde
 på med hobbyer de siste to ukene?
(How much have your joint or muscle symptoms interfered with your social activities and
 hobbies in the last 2 weeks?)
Ikke i det hele 















8. Behov for hjelp
(Needing help)
Hvor ofte har du trengt hjelp fra andre (inkludert familie, venner eller pleiere) på grunn
 av ledd-/muskelsymptomene de siste to ukene?
(How often have you needed help from others (including family, friends or carers) because




















Hvor ofte har du hatt problemer med søvn på grunn av ledd-/muskelsymptomene 
de siste to ukene?
(How often have you had trouble with either falling asleep or staying asleep because of your


















10. Utmattelse eller lite energi
(Fatigue or low energy)
Hvor mye utmattelse eller mangel på energi har du følt de siste to ukene?


















I hvilken grad har du vært engstelig eller nedtrykt på grunn av dine ledd-/muskelsymptomer
 de siste to ukene?
(How much have you felt anxious or low in your mood because of your joint or muscle symptoms

















12. Forståelse av dine helseplager og pågående behandling
(Understanding of your condition and any current treatment)
Når du tenker på ledd-/muskelsymptomene dine; hvor godt føler du at du forstår dine helse-
plager og din pågående behandling (inkludert din diagnose og medisinering)?
(Thinking about your joint or muscle symptoms, how well do you feel you understand your















Ikke i det hele tatt
(Not at all)
□ 0
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13. Tro på å mestre symptomene dine
(Confidence in being able to manage your symptoms)
Hvor sikker har du følt deg i din egen mestring av ledd-/muskelplagene de siste to ukene 
  (f.eks. medisinering eller endring av livsstil)?
(How confident have you felt in being able to manage your joint or muscle symptoms by yourself



















Samlet sett, hvor mye har dine ledd-/muskelsymptomer plaget deg de siste to ukene?
(How much have your joint or muscle symptoms bothered you overall in the last 2 weeks?)
Ikke i det hele 

















Hvor mange dager i løpet av den siste uken har du vært fysisk aktiv i 30 minutter eller mer? Den fysiske aktiviteten må ha vært anstrengende nok til å øke pulsen din. Aktiv-
iteten kan være idrett, trening, rask gange eller sykling. Husarbeid eller fysisk aktivitet som er en del av jobben din, skal ikke regnes med
(In the past week, on how many days have you done a total of 30 min or more of physical activity, which was enough to raise your heart rate? This may include sport, exercise and brisk 
walking or cycling for recreation or to get to and from places, but should not include housework


















CI: Confidence interval;; EQ-5D-5L: EuroQol 5 dimensions; HRQOL: Health-
related quality of life; ICPC-2: International Classification of Primary Care, 2nd 
edition; ICC: Intraclass correlation coefficient; iPCQ: Institute for Medical Tech-
nology Assessment Productivity Cost Questionnaire; Keele STarT MSK: Keele 
Subgroups for Targeted Treatment tool; L01: Neck symptom/complaint; L02: 
Back symptom/complaint; L03: Low back symptom/complaint; L08: Shoulder 
symptom/complaint; L13: Hip symptom/complaint; L15: Knee symptom/
complaint; L83: Neck syndrome; L84: Back syndrome without radiating pain; 
L85: Acuired deformity of spine; L86: Back syndrome with radiating pain; 
MSK-HQ: Musculoskeletal Health Questionnaire; NAV: Norwegian Welfare and 
Labor Administration; ÖMPSQ-SF: Örebro Musculoskeletal Pain Screening 
Questionnaire short form; PROMs: Patient-reported outcome measures; SEM: 
Standard error of measurement; SD: Standard deviation; SDC: Smallest detect-
able change.
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